[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection
This study is not yet open for participant recruitment.
Verified January 2013 by BioMed Valley Discoveries, Inc
Sponsor:
BioMed Valley Discoveries, Inc
Information provided by (Responsible Party):
BioMed Valley Discoveries, Inc
ClinicalTrials.gov Identifier:
NCT01764919
First received: January 7, 2013
Last updated: January 8, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This protocol will evaluate the sensitivity and specificity of [124I]FIAU as a diagnostic imaging agent for the detection of osteomyelitis in patients with diabetic foot infection.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetic Foot Infection |
Radiation: [124I]FIAU |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Exploration of the Use of [124I]FIAU Positron Emission Tomography-Computed Tomography Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection. |
Resource links provided by NLM:
Further study details as provided by BioMed Valley Discoveries, Inc:
Primary Outcome Measures:
- Assess the sensitivity and specificity of [124I]FIAU PET-CT scanning in detecting osteomyelitis as determined by bone biopsy in patients with diabetic foot infection. [ Time Frame: 30 hours ] [ Designated as safety issue: No ]Subjects will be dosed with [124I]FIAU. PET-CT scanning will be performed at two time points after dosing.
Secondary Outcome Measures:
- Assess the safety and tolerability of [124I]FIAU [ Time Frame: 30 +/- 2 days ] [ Designated as safety issue: Yes ]Safety will be monitored for all subjects for the duration of their study participation. Safety will be assessed by monitoring of adverse events,vital signs, physical exams, and clinical laboratory tests including CBC and serum chemistry.
- Compare the sensitivity and specificity of [124I]FIAU PET-CT scanning to gadolinium-enhanced (GE) magnetic resonance imaging (MRI) and non-GE-MRI scanning in detecting osteomyelitis in patients with diabetic foot infection [ Time Frame: -2 to 72 hours post dose [124I]FIAU ] [ Designated as safety issue: No ]All PET-CT images will be evaluated centrally and independently by a single radiologist. Diagnosis of osteomyelitis based on PET-CT will be compared with MRI which is currently the test of choice to diagnose osteomyelitis in diabetic foot infection.
- Assess any additional information that [124I]FIAU PET-CT scanning provides compared to MRI [ Time Frame: -2 to 72 hours post dose [124I]FIAU ] [ Designated as safety issue: No ]Additional information on the extent and localization of infection will be compared to MRI.
Other Outcome Measures:
- Explore the performance of [124I]FIAU PET-CT compared to MRI in detecting osteomyelitis by chronic kidney disease (CKD) stage (stage 1+2, stage 3, and stage 4+5). [ Time Frame: -2 hours to 72 hours post dose [124I]FIAU ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 25 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: [124I]FIAU
Single intravenous injection of [124I]FIAU in patients with diabetic foot infection
|
Radiation: [124I]FIAU
A single intravenous injection of 5 mCi[124I]FIAU in patients with diabetic foot infection who will undergo 2 PET-CT scanning.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male and female patients >/= 18 years on the day of signing consent.
- A diagnosis of diabetes mellitus, type I or II, as evidenced either by HbA1c>6.5% or receipt of antidiabetic medication at time of enrollment.
- Ability to provide informed consent
- An inframalleolar ulcer of perfusion, extent/size, depth/tissue loss, infection and sensation (PEDIS) grade 2 or 3. At the discretion of the Investigator, patients with PEDIS grade 4 infections may be included if they are sufficiently stable.
- For females of childbearing potential, a negative urine pregnancy test on the day of dosing.
- For females of childbearing potential, a willingness to use 2 methods of contraception for 30 days after receiving [124I]FIAU.
- Ability to return for all study assessments.
- Clinically euthyroid, or on stable thyroid replacement therapy.
Exclusion Criteria:
- Patients who ar unable to comply with study requirements.
- Indication, in the opinion of the principal Investigator for urgent surgery that would preclude the time needed for PET-CT scanning, or clinical instability that precludes PET-CT scanning.
- History of an inherited mitochondrial disorder (eg. Leber's hereditary neuropathy, neuropathy, ataxia, retinitis pigmentosa and ptosis [NARP], myoneurogenic gastrointestinal encephalopathy [MNGIE], myocolonic epilepsy with ragged red fibers [MERFF] and mitochondrial myopathy, encephalomyopathy, lactic acidosis and stroke-like syndrome [MELAS])
- Alanine aminotransferase (ALT)>5x Upper Limit of Normal (ULN) OR aspartate aminotransferase (AST) >5x ULN.
- Body mass that exceeds the rating of the CT table.
- Hypersensitivity to iodine.
- Pregnant or breast-feeding.
- Any condition that would put the patient at unreasonable risk in the opinion of the Investigator.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01764919
Contacts
| Contact: Catherine A Evershed, BS | 585-243-2206 | catherine.evershed@covance.com |
| Contact: Saurabh Saha, MD, PhD | 816-960-4661 | ssaha@biomed-valley.com |
Locations
| United States, Arizona | |
| The University of Arizona | Not yet recruiting |
| Tucson, Arizona, United States, 85724 | |
| Contact: Carol Stuehm 520-626-8318 carols@email.arizona.edu | |
| Principal Investigator: Phillip H Kuo, M.D., PhD | |
Sponsors and Collaborators
BioMed Valley Discoveries, Inc
More Information
No publications provided
| Responsible Party: | BioMed Valley Discoveries, Inc |
| ClinicalTrials.gov Identifier: | NCT01764919 History of Changes |
| Other Study ID Numbers: | BVD003 |
| Study First Received: | January 7, 2013 |
| Last Updated: | January 8, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Bone Diseases, Infectious Osteomyelitis Diabetic Foot Focal Infection Infection Bone Diseases Musculoskeletal Diseases Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Foot Ulcer Leg Ulcer |
Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies Fialuridine Antiviral Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 21, 2013